4th Quarter - Report

TIBER CREEK GROUP for MERCK & CO., INC

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; H.R. 7667 - Food and Drug Amendments of 2022; Consolidated Appropriations Act, 2023 (PL 117-328), Division FF, Title III - Food and Drug Administration, Subtitle B - Drugs and Biologics and Subtitle F, Chapter 1 - Clinical Trial Diversity and Modernization; H.R. 7559 - the Prescription Information Modernization Act; Package Inserts/eLabeling Issues (H.R. 7559 - Prescription Information Modernization Act of 2022).

LobbyistCovered position, as disclosed
JOHN MICHAEL GONZALEZ —
JONATHON JONES —
COREY MALMGREN —
ANDREW MCKECHNIE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 7667 (117th), H.R. 7559 (117th), S. 4348 (117th)

Medicare/Medicaid MMM

Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issues related to capping out-of-pocket costs.

LobbyistCovered position, as disclosed
JOHN MICHAEL GONZALEZ —
JONATHON JONES —
COREY MALMGREN —
ANDREW MCKECHNIE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

Issues relating to Intellectual Property protections for Covid-19 treatments and vaccines.

LobbyistCovered position, as disclosed
JOHN MICHAEL GONZALEZ —
JONATHON JONES —
COREY MALMGREN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.